| Project/Area Number |
23256006
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 海外学術 |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
HIYAMA Eiso 広島大学, 自然科学研究支援開発センター, 教授 (00218744)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAJIRI Tatsuro 京都府立医科大学, 医学(系)研究科(研究院), 教授 (80304806)
HISHIKI Tomoro 千葉県がんセンター(研究所), 発がん研究グループ, 主任医長 (00375776)
WATANABE Kenichiro 京都大学, 医学(系)研究科(研究院), 講師 (20324634)
OUE Takaharu 兵庫医科大学, 医学部, 准教授 (50314315)
IDA Kohmei 帝京大学, 医学部, 教授 (60313128)
KAMIMATSUSE Arata 広島大学, 病院, 病院助教 (90569881)
OGURA Kaoru 広島大学, 病院, 講師 (10346653)
ONITAKE Yoshiyuki 広島大学, 病院, 病院助教 (10448269)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KONDO Satoshi 名古屋市立大学, 医学(系)研究科(研究院), 講師 (50234935)
YANO Michihiro 秋田大学, 医学部附属病院, 講師 (40321997)
|
|---|
| Project Period (FY) |
2011-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥42,640,000 (Direct Cost: ¥32,800,000、Indirect Cost: ¥9,840,000)
Fiscal Year 2014: ¥11,310,000 (Direct Cost: ¥8,700,000、Indirect Cost: ¥2,610,000)
Fiscal Year 2013: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
Fiscal Year 2012: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
Fiscal Year 2011: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
|
|---|
| Keywords | 癌 / 薬剤反応性 / ゲノム / トランスレーショナルリサーチ / 医療・福祉 |
|---|
| Outline of Final Research Achievements |
Childhood hepatic tumor international consortium (CHIC) by Japanese study group for pediatric liver tumor (JPLT) and European and North American groups analyzed 1605 cases in their passed clinical trials and made up the common staging, pathology classification, and risk-stratification criteria. Future global collaborative clinical trial named as PHITT (Pediatric Hepatoblastoma International Therapeutic Trial) were designed. This trial induces central review system of imaging diagnosis, surgical guideline, and molecular markers identified by next-generation sequencing and becomes a one enabled to be participated from Asian countries.
|
